Ifinatamab deruxtecan by Daiichi Sankyo for Lymphoma: Likelihood of Approval

Ifinatamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Lymphoma.

FDA approves Moderna’s RSV vaccine, marking its second commercial product

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

June 1, 2024

Radiotherapy may cause low-grade intestinal inflammation in cancer survivors

Patients who have undergone pelvic radiotherapy may live with low-grade chronic inflammation of the lower intestine 20 years after the treatment. 0

September 29, 2023

Common cranberry can help improve performance of competitive athletes

Competitive athletes are always looking for an extra edge that can help them improve performance. According to a new study by Concordia researchers published in

March 20, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.